Indian pharmaceutical sector reports growth of 13.6% in December 2014
Boosted by price increases and product launches
December 2014 saw healthy growth of 13.6% in the Indian pharmaceutical sector. The growth contributors were higher by 5.3% on account of price increases initiated by some companies, and 3.2% due to new introductions in the market.
The growth caused by price increases was the highest in the last 12 months. Quarterly growth from Oct–Dec 2014 was 10.3%, compared with 6.5% in the corresponding quarter in 2013.
Four therapies outgrew market growth and 14 reported double-digit growth. The respiratory segment grew at 10%, gastrointestinal at 13.5%, pain and analgesics at 11.3%, and anti infectives at 5.2%. In the chronic category, the anti-diabetic market grew by 33.1% and cardiac by 18.2%.
Among other high growing therapies were dermatology, which grew by 19.6% and urology, up by 29.7%.
In terms of molecules, the Amoxycillin and Clavulanic ccid market grew by 8.2%, while Glimepiride and Metformin increased by 20%.
Paracetamol saw 5.6% growth, Atorvastatin 24.0%, Probiotic Microbes 26.9%, Cefixime 1.1% and Pantoprazole 15.3%.
Montelukast and Levocetirizine grew by 2.4%, Glimepiride, Metformin and Pioglitazone by 28.1%, Hydroquinone, Mometasone and Tretinoin by 34.7%, Voglibose, Metformin and Glimepiride by 57.0%, and Leveteracetam by 37.2%.